


Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1643
	Examiner Huff, Sheela Jitendra	



U.S. PATENT DOCUMENTS								
Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS								
Exam Initial	No.		Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.		OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
SJH		55	Nakao et al., 1997 Am J Gastroenterol. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. 92(6):1031-4.					
SJH		56	Wolf et al., 1993, J. Immunol. 150(8):p142A; Abstract No. 806 Immunohistological and Flowcytometry studies using monoclonal antibody					
SJH		57	Wolf et al., 1993, Immunoreactivity of cell lines and colon carcinomas with monoclonal antibodies PCA 31.1 and PCA 33.28. Mol. Biol. Cell 4 (supp): p334A; Abstract 1940					

546758	/Sheela J. Huff/	Date Considered	06/01/2006
Examiner			


* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1643
	Examiner Huff, Sheela Jitendra	

Exam Initial	N o.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
SJH	58	Wolf et al., 1993, Monoclonal antibody 31.1 may differentiate indolent from aggressive colon cancer. Proc. Am. Assoc. Cancer Res. 34: p452 ; Abstract 2695.
↓	59	Hurwitz et al., 1992, Immunotargeting of Daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. Cancer Immunol. Immunother. 35:186-192.
↓	60	Kuroki et al., 1992, Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analysed with purified preparations of CEA and related normal antigens. Clin. Biochem. 25:29-35
↓	61	Bartal et al., 1990, Monoclonal antibody defining an antigen present within a purified tumor membrane vaccine Proc. American Assoc. Cancer Res. 31: p260, Abstract No. 1537
↓	62	Tsang, 1987, Monoclonal antibodies to human colon carcinoma-associated antigens FASEB 46(3):1058, Abstract No. 4322.
SJH	63	Hughes et al., (1986) Antigen expression in normal and neoplastic colonic mucosa: three tissue-specific antigens using monoclonal antibodies to isolated colonic glands. Cancer Res. 46:2164-2171 (⁶).

546758			
Examiner	/Sheela J. Huff/	Date Considered	06/01/2006

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-148 U.S. Department of Commerce (Patent and Trademark Office) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1642
	Examiner To Be Assigned	L.R. Helms

U.S. PATENT DOCUMENTS								
*Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS								
Exam Initial	No.		Document No.	Date	Country	Class	Subclass	<u>Translation</u> Yes No

Exam Initial	N o.		OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
SJH		48	Proc. Am. Assoc. Cancer Res. 1994, Mar. Vol 35, Abstract 103, "Comparison of immunostaining of colonic neoplasms with PCA 31.1, PCA 33.28, B72-3 and anti-CEA monoclonal antibodies". A.H. Bartal, J. Wolf, H. Lichtig, E. Agranovsky, R. Levy, H. Kerner, V. Bychkov, O. Saric, M. Wolff, Y. Hirshaut, M. Monizur, M. Arlen and L. Pertschuk.					
SJH		49	J. Surg. Oncol. 1993, Vol 54, pages 103-108, "Monoclonal Antibodies and Their Role in Modulation of the Immune Response", Myron Arlen, J.D. and Kwong Y. Tsang, Ph.D.					
SJH		50	Ann. New York Acad Sci 1993, Vol, 690, pp. 374-375; "Identification and Characterization of a Colon Tumor-Associated Antigen". M. Arlen, A. C. Hollinshead and K. Y Tsang.					

NY02:534047.1


/Sheela J. Huff/

06/01/2006

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Tsang et al.	
	Filing Date August 4, 2000	Group 1642
	Examiner To Be Assigned	L.R. Helms

[illegible]

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
CENTRAL FAX CENTER

002

JUN 08 2006

PTO/SB/08B (06-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OIA control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/633,034
		Filing Date	Aug. 4, 2000
		First Named Inventor	Tsang, et al.
		Art Unit	1642
		Examiner Name	Sheela Huff
Attorney Docket Number	072771.0106		
Sheet	1	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJH	1	Bartal, A. H et al, Proc. Am Assoc. Can Res, 31:260 (Ast#1537), Mar. 1990.	
	2	Price, M.R et al, IRCS J Med Sci, 13(4):366-367, Apr. 1986.	
	3	Herlyn, M et al, PNAS, 76(3):1438-1442, Mar. 1979.	
	4	Tsang, K.Y. et al, Fed Proc, 46(3):1058 (Abst#4322), Mar. 1987.	
	5	Xu, Danlin, Dissertation (Degree 1990) order #9109383, pp. 1-86, 1990.	
	6	Kanellos, J et al, JNCI, 75(2):319-332, Aug. 1985.	
	7	Shaw, D.R et al, J Immunol, 138:4534-4538, Jun. 15, 1987.	
	8	Tsang, K.Y et al, FASEB, J2(5):A6815, 1988.	
	9	Hollinshead, A., et al., Science, 177: 887-889 (1972).	
SJH	10	Von Kleist, S., et al., Proc. Natl. Acad. Sci. USA 69: 2492-2494 (1972).	

Examiner Signature	/Sheela J. Huff/	Date Considered	06/20/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-0199 (1-800-788-0199) and select option 2.

**RECEIVED
CENTRAL FAX CENTER**

JUN 08 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/633,034
		Filing Date	Aug. 4, 2000
		First Named Inventor	Tsang, et al.
		Art Unit	1642
		Examiner Name	Sheela Huff
Sheet 2	of 6	Attorney Docket Number	072771.0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJH	11	Hollinshead, A.C., J. Nat. Cancer Instit. 52: 327-338 (1974).	
SJH	12	Hollinshead, A.C., Cancer, 34: 1235-1243 (1974).	
SJH	13	Hollinshead, A.C., Lung Cancer Progress in Therapeutic Research, pp. 501-520, Muggia, F., Rosenzweig, M. (ed.), Raven Press 1979 #	
SJH	14	Herlyn, M., et al. Proc. Natl. Acad. Sci. USA 79: 1438-1442 (1979).	
SJH	15	Hollinshead, A. et al., Tumor Progression, pp. 289-300, Crispen (ed) (1980).	
SJH	16	Herlyn, M., et al. J. Clinical Immunol. 2: 135-140 (1982).	
SJH	17	Hollinshead, A.C., et al., Cancer 49: 1387-1404 (1982).	
SJH	18	Moldofsky, P.J., et al., Radiology 149: 549-555 (1983).	
SJH	19	Buchegger, F., et al., J. Experimental Medicine 158: 413-427 (1983).	
SJH	20	Takita, J., et al., Cancer Immunol. Immunother. 20: 231-235 (1985).	

Examiner Signature	/Sheela J. Huff/	Date Considered	06/20/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	08/633,034
		Filing Date	Aug. 4, 2000
		First Named Inventor	Tsang, et al.
		Art Unit	1642
		Examiner Name	Sheela Huff
Sheet 3	of 6	Attorney Docket Number 072771.0106	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJH	21	Price, M.R., et al., IRCS Med. Sci. 13: 366-367 (1985).	
	22	Kanellos, J., et al., JNCI 75: 319-332 (1985).	
	23	Hollinshead, A., et al., Cancer 56: 480-489 (1985).	
	24	Stewart, T.H.M., et al., Lung Cancer: Current Status and Prospects for the Future-Ann. Clin. Conf. on Cancer 28: 351-374 1986	
	25	Tsang, K., et al., JNIC 77: 1175-1180 (1986).	
	26	Douillard, J.Y., et al., Hybridoma 5: 5139-5149 (1986).	
	27	Hollinshead, A., Biologic Drugs, Vaccines: Current Status and Future Directions, pp. 85-103, Springer Verlag (1986).	
	28	Tsang, K., et al., Fed Proc. 46:4322 (1987).	
	29	Shaw, D.R., et al., J. Immunology 138: 4532-4538 (1987).	
SJH	30	Tsang, K., et al., Cancer Detection and Prevention 11: 094 (1987).	

Examiner Signature	/Sheela J. Huff/	Date Considered	06/20/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/089 (05-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known.

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

60

Application Number	09/633,034
Filing Date	Aug. 4, 2000
First Named Inventor	Tsang, et al.
Art Unit	1642
Examiner Name	Sheela Huff
Attorney Docket Number	072771.0108

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJH	31	Tsang, K., et al., Fed. Proc. 6815 (1988).	
	32	Tsang, K., et al., 7th International Congress of Immunology, Abstract 125-46 (1989).	
	33	Bartel, A., et al., Proceedings 31: Abstract 1537 (1990).	
	34	Arlen, M. and Tsang, K., J. Tumor Marker Oncology 5: 313-319 (1990).	
	35	Hirschfield, L.S., et al., Federation of American Societies for Experimental Biology, Abstract 5708 (1991).	
	36	Xu, D.L., et al., Fed. Amer. Soc. Exper. Biol., Abstract 2109 (1991).	
	37	Hollinshead, A.C. and Stewart, T.H.M., Yale Journal of Biology and Medicine 54: 367-379 (1981).	
	38	Sears, H.F., et al., J. Clinical Immunol. 2: 141-149 (1982).	
	39	Arlen, M., et al., Antibody, Immunoconjugates, and Radiopharmaceuticals, 4: 895-905 (1991).	
SJH	40	Arlen, M., et al., Journal of Surgical Oncology 54: 103-108 (1991).	

Examiner
Signature

/Sheela J. Huff/

Date

Considered

06/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/089 (08-03)

Approved for use through 07/31/2008, GMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/633,034
		Filing Date	Aug. 4, 2000
		First Named Inventor	Taang, et al.
		Art Unit	1642
		Examiner Name	Sheela Huff
Sheet 6	of 6	Attorney Docket Number 072771.0106	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJH	41	Arlen, M., et al., NY Academy (cancer vaccines) 603-605 (1993).	
SJH	42	Fernado, A.D. et al., Miami Symp. Short Reports 3: 88 (1993).	
SJH	43	Girardet, C., et al., J. Immunology 136: 1497-1503 (1986)	
	44		
	45		
	46		
	47		
	48		
	49		
	50		

Examiner Signature	/Sheela J. Huff/	Date Considered	06/20/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED
CENTRAL FAX CENTER

007

JUN 08 2006

PTO/GB/D&A (08-09)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number 09/833,034
Filing Date Aug. 4, 2000
First Named Inventor Teang, et al.
Art Unit 1642
Examiner Name Sheela Huff
Attorney Docket Number 072771.0106

Sheet 6 of 6

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
SJH	1	US-	4,579,827	4/86	Sakamoto, et al.	
V	2	US-	4,699,880	10/87	Goldstein	
	SJH	3	US-	4,810,781	3/89	Hollinshead
	4	US-				
	5	US-				
	6	US-				
	7	US-				
	8	US-				
	9	US-				
	10	US-				
	11	US-				
	12	US-				
	13	US-				
	14	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

Examiner Signature	/Sheela J. Huff/	Date Considered	06/20/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

U.S. PATENT DOCUMENTS

Exam. Initial	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
SJH	11	6,346,249	February 12, 2002	Barbas III et al.			4/4/2000.
SJH	12	6,342,587	January 29, 2002	Barbas III et al.			10/22/1999
SJH	28	5,958,412	Sept. 28, 1999	Welt et al.			6/4/1997
SJH	33	5,712,369	January 27, 1998	Welt et al. Old et al.			2/2/1996.
I	39	5,643,550	July 1, 1997	Welt et al.			9/27/1994
V	47	5,160,723	November 3, 1991	Welt et al.			3/18/ 1991.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

NY02:524633.3

Examiner

Date Considered

11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
SM	1	Chong, G., F. T. Lee, et al. (2005). "Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma." Clin Cancer Res 11(13): 4818-26.
	2	Koppe, M. J., R. P. Bleichrodt, et al. (2005). "Radioimmunotherapy and colorectal cancer." Br J Surg 92(3): 264-276.
	3	Mallegol, J., G. van Niel, et al. (2005). "Phenotypic and functional characterization of intestinal epithelial exosomes." Blood Cells Mol Dis 35(1): 11-16.
	4	Scott, A. M., F. T. Lee, et al. (2005). "A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake." Clin Cancer Res 11(13): 4810-4817.
	5	Deckert, P. M., W. G. Bornmann, et al. (2004). "Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine." Int J Oncol 24(5): 1289-95.
	6	Joosten, C. E., L. S. Cohen, et al. (2004). "Glycosylation profiles of the human colorectal cancer A33 antigen naturally expressed in the human colorectal cancer cell line SW1222 and expressed as recombinant protein in different insect cell lines." Biotechnol Prog 20(4): 1273-9.
	7	Deckert, P. M., C. Renner, et al. (2003). "A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy." Br J Cancer 88(6): 937-9.
	8	Mao, Z., S. Song, et al. (2003). "Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel like factor." Oncogene 22(28): 4434-43.
	9	Welt et al., 2003, Phase I Study of Anticlon Cancer Humanized Antibody A331. Clinical Cancer Res. 9(4):1338-1346.

NY02:524633.3	Examiner <i>Stueft</i>	Date Considered <i>11/7/05</i>
---------------	------------------------	--------------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
55H	10	Welt, S., G. Ritter, et al. (2003). "Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer." Clin Cancer Res 9(4): 1347-53.
	13	Johnstone, C. N., S. J. White, et al. (2002). "Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression." J Biol Chem 277(37): 34531-9.
	14	Orlova, A., J. Hoglund, et al. (2002). "Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry." Cancer Biother Radiopharm 17(4): 385-96.
	15	van Niel, G. and M. Heyman (2002). "The epithelial cell cytoskeleton and intracellular trafficking. II. Intestinal epithelial cell exosomes: perspectives on their structure and function." Am J Physiol Gastrointest Liver Physiol 283(2): G251-5.
	16	Barendswaard, E. C., J. L. Humm, et al. (2001). "Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft." J Nucl Med 42(8): 1251-6.
	17	Lee, F. T., A. Rigopoulos, et al. (2001). "Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts." Cancer Res 61(11): 4474-82.
	18	Ritter, G., L. S. Cohen, et al. (2001). "Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33." Cancer Res 61(18): 6851-9.
	19	van Niel, G., G. Raposo, et al. (2001). "Intestinal epithelial cells secrete exosome-like vesicles." Gastroenterology 121(2): 337-49.
✓	20	Abud, H. E., C. N. Johnstone, et al. (2000). "The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium." Mech Dev 98(1-2): 111-4.

NY02:524633.3

Examiner

Sliff

Date Considered

11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
SDH	21	Deckert, P. M., A. Jungbluth, et al. (2000). "Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts." <i>Int J Cancer</i> 87(3): 382-90.
	22	Johnstone, C. N., N. C. Tebbutt, et al. (2000). "Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells." <i>Am J Physiol Gastrointest Liver Physiol</i> 279(3): G500-10.
	23	Rader, C., G. Ritter, et al. (2000). "The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies." <i>J Biol Chem</i> 275(18): 13668-76.
	24	Ruan, S., J. A. O'Donoghue, et al. (2000). "Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam." <i>J Nucl Med</i> 41(11): 1905-12.
	25	Sakamoto, J., H. Kojima, et al. (2000). "Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer." <i>Cancer Chemother Pharmacol</i> 46 Suppl: S27-32.
	26	Barendswaard, E. C., J. A. O'Donoghue, et al. (1999). "131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft." <i>J Nucl Med</i> 40(10): 1764-8.
	27	Miyazono, Y., Y. Kamogawa, et al. (1999). "Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells." <i>J Gastroenterol Hepatol</i> 14(10): 997-1003.
	29	Barendswaard, E. C., A. M. Scott, et al. (1998). "Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice." <i>Int J Oncol</i> 12(1): 45-53.
✓	30	Burgess, A. W. (1998). "Growth control mechanisms in normal and transformed intestinal cells." <i>Philos Trans R Soc Lond B Biol Sci</i> 353(1370): 903-9.

NY02:524633.3

Examiner

Date Considered

11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
STM	31	Moritz, R. L., G. Ritter, et al. (1998). "Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium." J Chromatogr A 798(1-2): 91-101.
	32	Tio, T. L. (1998). "Diagnosis and staging of esophageal carcinoma by endoscopic ultrasonography." Endoscopy 30 Suppl 1: A33-40.
	34	Catimel, B., M. Nerrie, et al. (1997). "Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies." J Chromatogr A 776(1): 15-30.
	35	Heath, J. K., S. J. White, et al. (1997). "The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily." Proc Natl Acad Sci U S A 94(2): 469-74.
	36	Ji, H., R. L. Moritz, et al. (1997). "Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33." Electrophoresis 18(3-4): 614-21.
	37	Ritter, G., L. S. Cohen, et al. (1997). "Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium." Biochem Biophys Res Commun 236(3): 682-6.
	38	Tschmelitsch, J., E. Barendswaard, et al. (1997). "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)." Cancer Res 57(11): 2181-6.
	40	No Author listed. (1996). "MoAb A33 shows promise in targeting colon cancer for radioimmunotherapy." Oncology (Huntingt) 10(4): 553.
	41	Antoniw, P., A. P. Farnsworth, et al. (1996). "Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)." Br J Cancer 74(4): 513-24.

NY02:524633.3

Examiner

Date Considered

11/7/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A33081-R 072771.0106	Serial No. 09/633,034
	Applicant Tsang <i>et al.</i>	
	Filing Date August 4, 2000	Group 1642
	Examiner Helms, L.R.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
SM	42	Daghighian, F., E. Barendswaard, et al. (1996). "Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody." J Nucl Med 37(6): 1052-7.
	43	Welt, S., A. M. Scott, et al. (1996). "Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer." J Clin Oncol 14(6): 1787-97.
	44	King, D. J., P. Antoniow, et al. (1995). "Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy." Br J Cancer 72(6): 1364-72.
	45	Scott, A. M., E. Rosa, et al. (1995). "In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody." Nucl Med Biol 22(4): 497-504.
↓	46	Welt et al., 1994, Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients With Advanced Colon Cancer. J. Clin. Oncol. 12:1561-71

NY02-524633.3	
Examiner <i>SM</i>	Date Considered 11/17/05

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.